Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AZ-Pfizer side effects: Partnership crossover casualties coming soon?

This article was originally published in Scrip

Executive Summary

As the Pfizer, AstraZeneca megamerger circus continues following meetings between UK government committees and both companies' chiefs executives (scripintelligence.com, 15 May 2014), Scrip has been investigating possible repercussions a takeover could have on the giant drug makers' smaller pharma and biotech partners.

You may also be interested in...



Deals Of The Year 2023 Winners Revealed

For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.

CGT Landscape: Recent Approvals, Deals And 2024 Catalysts

The last quarter of 2023 was an exciting one for the cell and gene therapy sector – with the first-ever approval for a CRISPR-based therapeutic in the US and an increase in Phase III trials in the overall CGT pipeline. 

Building A Biotech: Exploring ILC’s Hybrid Interferon Platform

Non-executive chair Peter Bains and Owain Millington, vice president of immunology and head of preclinical, discuss ILC Therapeutics’ platform technology, financing plans as well as the pros and cons of running a startup biotech in the UK.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC025328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel